SCHEMBL4863265

SCHEMBL4863265

CN(C(=O)c1ccc(I)cc1)c1cccc(C#N)c1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.54
HSD17B2 P37059 6/20 0.47
HSD17B1 P14061 5/20 0.47
CLK1 P49759 1/20 0.42
HSD17B10 Q99714 2/20 0.41
HTT P42858 2/20 0.41
KDM4E B2RXH2 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KMT2A Q03164 3/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
PDK1 Q15118 1/20 0.40
KCNN4 O15554 1/20 0.40
KCNA5 P22460 1/20 0.40
TSHR P16473 1/20 0.39
HIF1A Q16665 1/20 0.39
EPAS1 Q99814 1/20 0.39
GSK3B P49841 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4908079 0.95 MAPK14 (0.51) MAPK14HSD17B2HSD17B1CLK1HSD17B10
SCHEMBL2894252 0.87 MAPK14 (0.55) MAPK14HSD17B2HSD17B1HSD17B10HTT
SCHEMBL665128 0.84 HSD17B2 (0.66) MAPK14HSD17B2HSD17B1CLK1KDM4E
SCHEMBL12574227 0.82 MAPK14 (0.46) MAPK14CLK1HSD17B10HTTKMT2A
SCHEMBL18816698 0.78 HSD17B10 (0.54) MAPK14HSD17B10HTTKDM4ESMN1; SMN2
SCHEMBL17265581 0.77 MAPK14 (0.45) MAPK14CLK1HSD17B10KMT2AMEN1
SCHEMBL29273240 0.76 KMT2A (0.62) HTTKDM4EKMT2AMEN1NPC1
SCHEMBL11361207 0.74 MAPK14 (0.42) MAPK14CLK1HTTKMT2AMEN1
SCHEMBL21776422 0.74 KMT2A (0.46) MAPK14CLK1KMT2AMEN1KCNN4
SCHEMBL2092641 0.74 PGR (0.46) MAPK14CLK1KMT2AMEN1KCNN4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384963-B2 2′-Methyl-5-(1,3,4-oxadiazol-2-yl)1, 1′-biphenyl-4-carboxaide derivatives and their use as p38 kinase GLAXO GROUP LIMITED (GB) 2008-06-10 US disclosed
US-20040266839-A1 2'-Methyl-5-(1,3,4-oxadiazol-2-yl)1,1'-biphenyl-4-carboxaide derivatives and their use as p38 kinase inhibitors GLAXO GROUP LIMITED (GB) 2004-12-30 US disclosed
EP-1435949-A1 2' -METHYL-5-(1,3,4-OXADIAZOL-2-YL)-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-07-14 EP disclosed
WO-2003032986-A1 2' -METHYL-5-(1,3,4-OXADIAZOL-2-YL)-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2003-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266839-A1 2'-Methyl-5-(1,3,4-oxadiazol-2-yl)1,1'-biphenyl-4-carboxaide derivatives and their use as p38 kinase inhibitors MAPK1, MAPK3, MAPK6 MAPK14 11/4885HSD17B2 864/4885HSD17B1 941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.